Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SPR005
MIFTS: 44

Superficial Basal Cell Carcinoma

Categories: Cancer diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Superficial Basal Cell Carcinoma

About this section

MalaCards integrated aliases for Superficial Basal Cell Carcinoma:

Name: Superficial Basal Cell Carcinoma 12 15 70
Multifocal Superficial Basal Cell Carcinoma 12 70
Superficial Multicentric Basal-Cell Carcinoma 12
Multicentric Basal Cell Carcinoma 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4300
NCIt 50 C4108
SNOMED-CT 67 61098004
UMLS 70 C0334256 C0862889
Sources

Summaries for Superficial Basal Cell Carcinoma

About this section
MalaCards based summary : Superficial Basal Cell Carcinoma, also known as multifocal superficial basal cell carcinoma, is related to vitiligo-associated multiple autoimmune disease susceptibility 1 and skin carcinoma. An important gene associated with Superficial Basal Cell Carcinoma is TLR7 (Toll Like Receptor 7), and among its related pathways/superpathways are Innate Immune System and Viral mRNA Translation. The drugs Imiquimod and Aminolevulinic acid have been mentioned in the context of this disorder. Affiliated tissues include breast, skin and t cells, and related phenotypes are hematopoietic system and cellular

Sources

Related Diseases for Superficial Basal Cell Carcinoma

About this section

Diseases related to Superficial Basal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 569)
# Related Disease Score Top Affiliating Genes
1 vitiligo-associated multiple autoimmune disease susceptibility 1 29.8 TNF IL2 CD8A CD4
2 skin carcinoma 28.9 TNF TLR9 TLR8 TLR7 IL6 IL2
3 psoriasis 28.9 TNF TLR9 TLR2 IL6 IL2 CD4
4 dermatitis 28.4 TNF TLR9 TLR2 IL6 IL2 CD8A
5 anogenital venereal wart 28.1 TLR9 TLR8 TLR7 TLR5 TLR4 TLR3
6 basal cell carcinoma 11.1
7 keratosis 10.5
8 in situ carcinoma 10.5
9 actinic keratosis 10.4
10 bowen's disease 10.4
11 micronodular basal cell carcinoma 10.4 TLR7 IFNA1
12 nodular basal cell carcinoma 10.4
13 ocular toxoplasmosis 10.3 TLR9 TLR5
14 fungal keratitis 10.3 TLR4 TLR2
15 marburg hemorrhagic fever 10.3 IFNA1 CD8A
16 juvenile nasopharyngeal angiofibroma 10.3 TLR9 TLR7 TLR3
17 chilblain lupus 1 10.3 TLR9 TLR7 IFNA1
18 endometrial mixed adenocarcinoma 10.3 TLR2 MYD88
19 squamous cell carcinoma 10.2
20 melanoma 10.2
21 microphthalmia with limb anomalies 10.2 TLR7 TLR3 IFNA1
22 wissler-fanconi syndrome 10.2 IFNA1 CD4
23 chronic purulent otitis media 10.2 TLR4 TLR2
24 neisseria meningitidis infection 10.2 TLR4 TLR2
25 cork-handlers' disease 10.2 CD8A CD4
26 necrotic uveal melanoma 10.2 CD8A CD4
27 meningococcal meningitis 10.2 TLR9 TLR4 TLR2
28 pouchitis 10.2 TNF TLR4
29 spondylarthropathy 10.2 TNF TLR4
30 gastrointestinal tularemia 10.2 TLR4 TLR2 MYD88
31 silo filler's disease 10.2 TLR4 TLR2 MYD88
32 early yaws 10.2 CD8A CD4
33 ventilation pneumonitis 10.2 CD8A CD4
34 haemophilus influenzae 10.2 TNF TLR2
35 diffuse infiltrative lymphocytosis syndrome 10.2 CD8A CD4
36 vitiligo-associated multiple autoimmune disease susceptibility 6 10.2
37 scrotum basal cell carcinoma 10.2
38 pustulosis of palm and sole 10.2
39 latent syphilis 10.2 CD8A CD4
40 autoimmune lymphoproliferative syndrome, type iia 10.2 CD8A CD4
41 nontuberculous mycobacterial lung disease 10.1 TNF TLR2
42 parapsoriasis 10.1 CD8A CD4
43 gastroduodenitis 10.1 CD8A CD4
44 primary syphilis 10.1 CD8A CD4
45 norwegian scabies 10.1 CD8A CD4
46 bird fancier's lung 10.1 CD8A CD4
47 listeria meningitis 10.1 TNF CD8A
48 variola major 10.1 CD8A CD4
49 mycobacterium abscessus 10.1 TNF TLR2
50 follicular mucinosis 10.1 CD8A CD4

Graphical network of the top 20 diseases related to Superficial Basal Cell Carcinoma:



Diseases related to Superficial Basal Cell Carcinoma
Sources

Symptoms & Phenotypes for Superficial Basal Cell Carcinoma

About this section

MGI Mouse Phenotypes related to Superficial Basal Cell Carcinoma:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.25 CD4 CD8A IL2 IL6 MYD88 TLR2
2 cellular MP:0005384 10.24 CD4 CD8A IL2 IL6 MYD88 TLR2
3 homeostasis/metabolism MP:0005376 10.18 CD4 IL2 IL6 MYD88 TLR2 TLR3
4 immune system MP:0005387 10.18 CD4 CD8A IL2 IL6 MYD88 TLR2
5 digestive/alimentary MP:0005381 10.13 CD4 IL2 IL6 MYD88 TLR2 TLR4
6 endocrine/exocrine gland MP:0005379 10.11 CD4 CD8A IL2 IL6 MYD88 TLR2
7 mortality/aging MP:0010768 10.03 CD4 CD8A IL2 IL6 MYD88 TLR2
8 liver/biliary system MP:0005370 9.87 IL2 IL6 MYD88 TLR2 TLR4 TLR5
9 neoplasm MP:0002006 9.7 IL2 IL6 MYD88 TLR2 TLR3 TLR4
10 renal/urinary system MP:0005367 9.56 CD8A IL6 MYD88 TLR2 TLR4 TLR7
11 respiratory system MP:0005388 9.23 IL2 IL6 MYD88 TLR2 TLR3 TLR4
Sources

Drugs & Therapeutics for Superficial Basal Cell Carcinoma

About this section

Drugs for Superficial Basal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 10)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
2
Aminolevulinic acid Approved Phase 3 106-60-5 137
3 Adjuvants, Immunologic Phase 3
4 Immunologic Factors Phase 3
5 interferons Phase 3
6 Tea Phase 2, Phase 3
7 Photosensitizing Agents Phase 3
8 Dermatologic Agents Phase 3
9 Methyl 5-aminolevulinate Phase 1
10
Vitamin C Approved, Nutraceutical 50-81-7 5785 54670067

Interventional clinical trials:

(show all 18)
# Name Status NCT ID Phase Drugs
1 Treatment of Superficial Basal Cell Carcinoma by Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Topical Photodynamic Therapy With Methylaminolevulinate Unknown status NCT01491711 Phase 4 Methylaminolevulinate PDT in 2 sessions;Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
2 A Multicenter, Phase III, Randomised Study of Photodynamic Therapy With Metvix Cream 160 mg/g in Comparison With Cryotherapy in Patients With Primary Superficial Basal Cell Carcinoma Completed NCT00469417 Phase 3
3 An Open-label Study to Evaluate the Safety and Long-Term Clinical Efficacy of Imiquimod 5% Cream Applied Once Daily 7 Days Per Week for 6 Weeks in the Treatment of Superficial Basal Cell Carcinoma Completed NCT00189306 Phase 3 Imiquimod 5% cream
4 An Open-Label Study to Evaluate the Safety and Long-Term Clinical Efficacy of Imiquimod 5% Cream Applied Once Daily 5 Days Per Week for 6 Weeks in the Treatment of Superficial Basal Cell Carcinoma Completed NCT00189241 Phase 3 imiquimod
5 A Randomized Controlled Trial of Excisional Surgery Versus Imiquimod 5% Cream for Nodular and Superficial Basal Cell Carcinoma Completed NCT00066872 Phase 3 imiquimod
6 Open Study to Evaluate the Efficacy and Tolerance of Imiquimod 5% Cream for the Treatment of a Large and/or Multiple Superficial Basal Cell Carcinoma. Completed NCT00189280 Phase 3 Imiquimod
7 Topical Sinecatechins Ointment in Treatment of Primary Superficial Basal Cell Carcinoma: a Double Blind, Randomized, Placebo-controlled Trial. Completed NCT02029352 Phase 2, Phase 3 Sinecatechins 10%;Placebo
8 A Randomized, Double Blind, Vehicle-controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). Recruiting NCT03573401 Phase 3
9 An Open-label, Multi-center, Dose-escalation, Cohort Study to Determine the Maximum Tolerated Dose and Safety of PEP005 Topical Gel Given as Either a Single Application (on Day 1) or as Two Applications (on Day 1 and Day 8) to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk. Completed NCT00432185 Phase 2 PEP005
10 Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma Completed NCT00604890 Phase 1, Phase 2 API 31510 3% Topical Cream;API 31510 1.5% Topical Cream
11 A Phase 2 Multi-centre, Parallel Group, Open Label Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Administered for up to Three Consecutive Days to a Superficial Basal Cell Carcinoma (sBCC) on the Trunk or Extremities Completed NCT01325688 Phase 2 PEP005 (ingenol mebutate) Gel, 0.05%
12 A Multi-Center, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study to Determine the Safety of PEP005 0.0025%, 0.01% and 0.05% Gel With Two Treatment Schedules, Day 1 & 2 or Day 1 & 8 Applications to Superficial Basal Cell Carcinoma Completed NCT00108134 Phase 2 PEP005
13 An Exploratory Study to Evaluate the Safety and Efficacy of AIV001 Intradermally Administered in Subjects With Biopsy-confirmed Basal Cell Carcinoma Recruiting NCT04470726 Phase 1, Phase 2 AIV001
14 A Phase I Study for Superficial Basal Cell Carcinoma to Determine the Irradiance - Dependent Pain Threshold for Methylaminolevulinate (MAL)/PDT. Completed NCT01292668 Phase 1 methyl-5-aminolevulinate hydrochloride cream;photodynamic therapy
15 Cytodiagnosis of Basal Cell Carcinoma and Actinic Keratosis Using Papanicolaou and May-grunvald-giemsa Stained Cutaneous Tissue Smear in Relation to Photodynamic Therapy Completed NCT00218868
16 The Role of the 595 nm Pulsed Dye Laser in Treating Superficial Basal Cell Carcinomas at Low Risk Anatomical Sites: Outcome of a Double Blind Randomized Placebo Controlled Trial Completed NCT02125669
17 Prospective Randomized Trial: Curettage Versus Excision in Nodular and Superficial Basal Cell Carcinomas Suspended NCT00515970
18 Cure Rates of Superficial Basal Cell Carcinoma Following 1 Versus 3 Cycles of Electrodessication & Curettage: A Randomized Prospective Study Terminated NCT00994240

Search NIH Clinical Center for Superficial Basal Cell Carcinoma

Sources

Genetic Tests for Superficial Basal Cell Carcinoma

About this section
Sources

Anatomical Context for Superficial Basal Cell Carcinoma

About this section

MalaCards organs/tissues related to Superficial Basal Cell Carcinoma:

40
Breast, Skin, T Cells
Sources

Publications for Superficial Basal Cell Carcinoma

About this section

Articles related to Superficial Basal Cell Carcinoma:

(show top 50) (show all 350)
# Title Authors PMID Year
1
Persistence of superficial basal cell carcinoma during pembrolizumab treatment for metastatic melanoma. 61
33586650 2021
2
Treatment of superficial basal cell carcinoma with 7.8% 5-aminolaevulinic acid nanoemulsion-based gel (BF-200 ALA) and photodynamic therapy: Results in clinical practice in a tertiary hospital. 61
33210436 2021
3
Mucosal side effects in patients treated with topical imiquimod-A scoping review of the literature. 61
32990395 2021
4
Nanocarriers for Photodynamic Therapy Intended to Cutaneous Tumors. 61
33397257 2021
5
Growth rate of clinically diagnosed superficial basal cell carcinoma and changes in dermoscopic features over time. 61
32578200 2020
6
Development of a patient decision aid for superficial basal cell carcinoma. 61
33131075 2020
7
Superficial Basal Cell Carcinoma of the Face Successfully Treated with Ingenol Mebutate 0.05% Gel: Case Report and a Review of the Literature. 61
33584954 2020
8
Sequential Treatment of Superficial Basal Cell Carcinomas With Topical Methyl Aminolevulinate Photodynamic Therapy and Imiquimod 5% Cream: A Retrospective Study of Clinical and Cosmetic Outcomes. 61
32011386 2020
9
Basal Cell and Cutaneous Squamous Cell Carcinomas: Diagnosis and Treatment. 61
32931212 2020
10
Topical Imiquimod for Management of Recurrent Lentigo Maligna Melanoma in Situ. 61
32650849 2020
11
Giant Superficial Basal Cell Carcinoma Diagnosed and Treated as Psoriasis: Report of Two Cases and a Literature Review. 61
32516426 2020
12
Superficial Basal Cell Cancers Demonstrate Higher Rates of Mixed Histology on High-Risk Anatomical Sites. 61
31652222 2020
13
Topical Fluorouracil Therapy for Residual Superficial Basal Cell Carcinoma Following Mohs Micrographic Surgery. 61
32484617 2020
14
Development of a patient decision aid for the management of superficial basal cell carcinoma (BCC) in adults with a limited life expectancy. 61
32349762 2020
15
Unusual presentation of Kaposi sarcoma in an HIV-negative woman. 61
32621687 2020
16
Exploratory Assessment of Oxygen Flow-Assisted Cutaneous Administration of Methotrexate for Superficial Basal Cell Carcinoma, Mycosis Fungoides, and Extramammary Paget Disease. 61
31513804 2020
17
Diagnosis and treatment of low-risk superficial basal cell carcinoma in a single visit. 61
32116084 2020
18
An audit of pain scores with conventional and white light topical 5-methyl aminolaevulinic acid photodynamic therapy for superficial basal cell carcinoma and squamous cell carcinoma in situ. 61
31613393 2020
19
[Dermoscopic signs as predictors of non-response to imiquimod treatment in superficial basal cell carcinoma]. 61
31859267 2019
20
Topical Imiquimod and Subsequent Erythema Multiforme. 61
31841130 2019
21
The effectiveness of imiquimod 5% cream as an anti-wrinkle treatment: A pilot study. 61
30941881 2019
22
Photodynamic therapy: A targeted literature review focussing on outcomes and optimisation in solid organ transplant recipients. 61
31012102 2019
23
Basal Cell Carcinoma Originating in a Tattoo: Case Report and Review of an Uncommon Complication in Tattoo Recipients. 61
31723458 2019
24
Pulsed dye laser in the treatment of basal cell carcinoma: A single session versus two sessions - a randomized controlled trial. 61
31062722 2019
25
Photodynamic therapy in superficial basal cell carcinoma treatment. 61
31349099 2019
26
Treatment of superficial basal cell carcinoma with photodynamic therapy. Observational study in 22 patients with 5-aminolaevulinic acid and methyl aminolaevulinate. 61
30914392 2019
27
Topical Imiquimod Induces Severe Weakness and Myalgias After Three Applications: A Case Report. 61
31360290 2019
28
Complete Resolution of Primary Cutaneous Anaplastic Large Cell Lymphoma With Topical Imiquimod 61
31141854 2019
29
Immunocryosurgery for non-superficial basal cell carcinomas ≤ 20 mm in maximal diameter: Five-year follow-up. 61
30219274 2019
30
Histologic subtype of treatment failures after noninvasive therapy for superficial basal cell carcinoma: An observational study. 61
30582993 2019
31
Mohs Appropriate Use Criteria for Superficial Basal Cell Carcinoma. 61
30725082 2019
32
Mohs Appropriate Use Criteria for Superficial Basal Cell Carcinoma. 61
30725085 2019
33
Mohs Appropriate Use Criteria for Superficial Basal Cell Carcinoma-Reply. 61
30725098 2019
34
Sequential treatment of daylight photodynamic therapy and imiquimod 5% cream for the treatment of superficial basal cell carcinoma on sun exposed areas. 61
30499211 2019
35
Mohs Appropriate Use Criteria for Superficial Basal Cell Carcinoma. 61
30725088 2019
36
Is a single day patient friendly methyl aminolevulinate photodynamic therapy illumination scheme for superficial basal cell carcinoma feasible? A randomized multicenter pilot trial. 61
29862877 2019
37
Basal Cell Carcinoma Associated with Secondary Localized Cutaneous Amyloid Deposits: Case Report and Review. 61
30899630 2019
38
Regression Analysis of Protoporphyrin IX Measurements Obtained During Dermatological Photodynamic Therapy. 61
30634715 2019
39
Design, Development, and Characterization of Imiquimod-Loaded Chitosan Films for Topical Delivery. 61
30623265 2019
40
Accuracy of dermoscopic criteria for the differentiation between superficial basal cell carcinoma and Bowen's disease. 61
29633377 2018
41
Laser-assisted photodynamic therapy for superficial basal cell carcinoma and Bowen's disease: a randomized intrapatient comparison between a continuous and a fractional ablative CO2 laser mode. 61
29633367 2018
42
Comparison of long-term cosmetic outcomes for different treatments of superficial basal cell carcinoma. 61
29753062 2018
43
Topical 5-fluorouracil in dermatologic disease. 61
30187924 2018
44
Reevaluating Mohs Surgery Appropriate Use Criteria for Primary Superficial Basal Cell Carcinoma. 61
29516099 2018
45
Immune consequences induced by photodynamic therapy in non-melanoma skin cancers: a review. 61
29948701 2018
46
Cryosurgery + 5% 5-Fluorouracil for Treatment of Superficial Basal Cell Carcinoma and Bowen's Disease [Formula: see text]. 61
29457484 2018
47
Imiquimod-induced hypopigmentation following treatment of periungual verruca vulgaris. 61
30063776 2018
48
Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5-aminolaevulinic acid 20% vs. two-stage topical methyl aminolaevulinate: results of a randomized controlled trial. 61
28886209 2018
49
Five-Year Results of a Randomized Controlled Trial Comparing Effectiveness of Photodynamic Therapy, Topical Imiquimod, and Topical 5-Fluorouracil in Patients with Superficial Basal Cell Carcinoma. 61
29045820 2018
50
Comparing Topical Treatments for Basal Cell Carcinoma. 61
29395168 2018
Sources

Variations for Superficial Basal Cell Carcinoma

About this section
Sources

Expression for Superficial Basal Cell Carcinoma

About this section
Search GEO for disease gene expression data for Superficial Basal Cell Carcinoma.
Sources

Pathways for Superficial Basal Cell Carcinoma

About this section

Pathways related to Superficial Basal Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 62)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.05 TNF TLR9 TLR8 TLR7 TLR5 TLR4
2
Viral mRNA Translation 65
Show member pathways
 13.83 TNF TLR8 TLR7 TLR4 TLR3 TLR2
3
Activated TLR4 signalling 65
Show member pathways
 13.61 TLR9 TLR8 TLR7 TLR5 TLR4 TLR3
4
Akt Signaling 63
Show member pathways
 13.47 TNF TLR9 TLR8 TLR7 TLR5 TLR4
5
IL-2 Pathway 63
Show member pathways
 13.33 TNF TLR9 TLR8 TLR7 TLR5 TLR4
6
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 13.3 TNF TLR9 TLR8 TLR7 TLR5 TLR4
7
PI3K-Akt signaling pathway 36
Show member pathways
 13.04 TNF TLR4 TLR3 TLR2 IL6 IL2
8
Human cytomegalovirus infection 36
Show member pathways
 13.03 TNF TLR4 TLR3 TLR2 MYD88 IL6
9
Measles 36
Show member pathways
 12.97 TNF TLR9 TLR7 TLR4 TLR3 TLR2
10
Allograft rejection 1 36
Show member pathways
 12.9 TNF IL6 IL2 IFNA1 CD8A CD4
11
Herpes simplex virus 1 infection 36
12.89 TNF TLR9 TLR3 TLR2 MYD88 IL6
12
Salmonella infection (KEGG) 36
Show member pathways
 12.84 TNF TLR9 TLR5 TLR4 TLR2 MYD88
13
T cell receptor signaling pathway 36
Show member pathways
 12.76 TNF TLR9 TLR4 TLR2 MYD88 IL6
14
TRAF Pathway 63
Show member pathways
 12.73 TNF TLR9 TLR8 TLR7 TLR5 TLR4
15
Th17 cell differentiation 36
Show member pathways
 12.71 TNF TLR5 TLR4 TLR2 IL6 IL2
16
NF-kappaB Signaling 4
12.69 TNF TLR9 TLR8 TLR7 TLR3 TLR2
17
VEGF Pathway (Qiagen) 63
Show member pathways
 12.57 TLR9 TLR8 TLR7 TLR5 TLR4 TLR3
18
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.57 TNF TLR9 TLR8 TLR7 TLR5 TLR4
19
Immune response IL-23 signaling pathway 23
Show member pathways
 12.56 TNF IL6 IL2 CD4
20
Cytosolic sensors of pathogen-associated DNA 65
Show member pathways
 12.53 TLR3 MYD88 IL6 IFNA1
21
Antigen processing-Cross presentation 65
Show member pathways
 12.47 TLR4 TLR2 MYD88 CD8A
22
Tuberculosis 36
12.42 TNF TLR9 TLR4 TLR2 MYD88 IL6
23
Shigellosis 36
12.41 TNF TLR5 TLR4 MYD88
24
Toll Comparative Pathway 63
Show member pathways
 12.38 TNF TLR4 TLR3 MYD88 IL6
25
Human T-cell leukemia virus 1 infection 36
12.36 TNF IL6 IL2 CD4
26
IL-17 Family Signaling Pathways 64
Show member pathways
 12.35 TNF TLR5 TLR2 IL6
27
C-type lectin receptor signaling pathway 36
Show member pathways
 12.34 TNF TLR9 TLR8 MYD88 IL6 IL2
28
NOD-like receptor signaling pathway 36
12.32 TNF TLR4 MYD88 IL6 IFNA1
29
Bacterial infections in CF airways 23
Show member pathways
 12.3 TNF TLR9 TLR8 TLR7 TLR5 TLR4
30
Toxoplasmosis 36
Show member pathways
 12.28 TNF TLR4 TLR2 MYD88
31
Yersinia infection 36
12.28 TNF TLR4 MYD88 IL6 IL2 CD8A
32
Diseases associated with the TLR signaling cascade 65
Show member pathways
 12.28 TNF TLR9 TLR8 TLR7 TLR5 TLR4
33
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.24 TNF IL6 IL2 IFNA1
34
Colorectal Cancer Metastasis 63
12.24 TNF TLR9 TLR8 TLR7 TLR5 TLR4
35
Necroptosis 36
Show member pathways
 12.23 TNF TLR4 TLR3 IFNA1
36
MAPK Pathway 69
Show member pathways
 12.15 TLR9 TLR8 TLR7 TLR5 TLR4 TLR3
37
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
12.11 TNF IL6 IL2 CD8A CD4
38
Spinal Cord Injury 1
12.07 TNF TLR4 IL6 IL2
39
Th17 Differentiation Pathway 64
Show member pathways
 12.03 TLR9 TLR8 TLR7 TLR5 TLR4 TLR3
40
NF-KappaB Family Pathway 63
Show member pathways
 12.02 TNF TLR9 TLR8 TLR7 TLR5 TLR4
41
Amoebiasis 36
12 TNF TLR4 TLR2 IL6
42
Phagocytosis of Microbes 63
11.99 TLR9 TLR8 TLR7 TLR5 TLR4 TLR3
43
Hematopoietic cell lineage 36
11.98 TNF IL6 CD8A CD4
44
IL12-mediated signaling events 1
Show member pathways
 11.96 IL2 CD8A CD4
45
Rheumatoid arthritis 36
11.95 TNF TLR4 TLR2 IL6
46
Dendritic Cells Developmental Lineage Pathway 64
11.95 TNF TLR9 TLR7 IL6 IL2 CD8A
47
NF-kappa B signaling pathway 36
11.92 TNF TLR4 MYD88
48
IgA-Producing B Cells in the Intestine 64
11.91 TNF TLR9 TLR5 TLR4 TLR2 IL6
49
Cytokine production by Th17 cells in CF (Mouse model) 23
Show member pathways
 11.87 TLR4 MYD88 IL6
50
Innate Lymphoid Cell Differentiation Pathways 64
11.87 TNF IL2 CD8A CD4
Sources

GO Terms for Superficial Basal Cell Carcinoma

About this section

Cellular components related to Superficial Basal Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.17 TNF TLR9 TLR8 TLR7 TLR5 TLR4
2 plasma membrane GO:0005886 10.06 TNF TLR9 TLR8 TLR7 TLR5 TLR4
3 endosome GO:0005768 9.85 TLR9 TLR8 TLR7 TLR4 TLR3
4 cell surface GO:0009986 9.77 TNF TLR4 TLR3 TLR2 CD4
5 integral component of plasma membrane GO:0005887 9.76 TNF TLR5 TLR4 TLR3 TLR2 TLR10
6 external side of plasma membrane GO:0009897 9.65 TNF TLR8 TLR4 CD8A CD4
7 endosome membrane GO:0010008 9.43 TLR9 TLR8 TLR7 TLR4 TLR3 MYD88
8 early phagosome GO:0032009 9.4 TLR9 TLR7
9 endolysosome membrane GO:0036020 8.92 TLR9 TLR8 TLR7 TLR3

Biological processes related to Superficial Basal Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.39 TLR9 TLR8 TLR7 TLR5 TLR4 TLR3
2 innate immune response GO:0045087 10.26 TLR9 TLR8 TLR7 TLR5 TLR4 TLR3
3 positive regulation of transcription by RNA polymerase II GO:0045944 10.24 TNF TLR9 TLR4 TLR3 TLR2 IL6
4 immune system process GO:0002376 10.23 TLR9 TLR8 TLR7 TLR5 TLR4 TLR3
5 positive regulation of gene expression GO:0010628 10.19 TNF TLR9 TLR4 TLR3 TLR2 MYD88
6 cytokine-mediated signaling pathway GO:0019221 10.14 TNF MYD88 IL6 IL2 IFNA1 CD4
7 defense response to bacterium GO:0042742 10.12 TNF TLR9 TLR5 TLR4 TLR3 MYD88
8 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.12 TNF TLR9 TLR4 TLR3 TLR2 MYD88
9 defense response to virus GO:0051607 10.11 TLR9 TLR8 TLR7 TLR3 IL6 IFNA1
10 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.1 TNF TLR9 TLR4 TLR3 MYD88 CD4
11 positive regulation of tumor necrosis factor production GO:0032760 10.08 TLR9 TLR4 TLR3 TLR2 MYD88 IL6
12 cellular response to lipopolysaccharide GO:0071222 10.07 TNF TLR5 TLR4 MYD88 IL6
13 cellular response to mechanical stimulus GO:0071260 10.06 TLR8 TLR7 TLR5 TLR4 TLR3 MYD88
14 positive regulation of JNK cascade GO:0046330 10.03 TNF TLR9 TLR4 TLR3 MYD88
15 positive regulation of NIK/NF-kappaB signaling GO:1901224 10.03 TNF TLR9 TLR7 TLR4 TLR3 TLR2
16 positive regulation of inflammatory response GO:0050729 10.03 TNF TLR9 TLR7 TLR4 TLR3 TLR2
17 I-kappaB kinase/NF-kappaB signaling GO:0007249 10.02 TNF TLR9 TLR8 TLR7 TLR4 TLR3
18 positive regulation of interferon-gamma production GO:0032729 10.02 TNF TLR9 TLR8 TLR7 TLR4 TLR3
19 positive regulation of chemokine production GO:0032722 10.01 TNF TLR9 TLR7 TLR4 TLR3 TLR2
20 response to virus GO:0009615 9.99 TNF TLR8 TLR3 MYD88
21 defense response to Gram-positive bacterium GO:0050830 9.99 TNF TLR2 MYD88 IL6
22 microglial cell activation GO:0001774 9.99 TNF TLR8 TLR7 TLR3 TLR2
23 positive regulation of interferon-beta production GO:0032728 9.99 TLR9 TLR8 TLR7 TLR4 TLR3 TLR2
24 defense response to Gram-negative bacterium GO:0050829 9.98 TLR9 TLR4 IL6 CD4
25 positive regulation of interleukin-1 beta production GO:0032731 9.97 TNF TLR8 TLR4 IL6
26 positive regulation of interferon-alpha production GO:0032727 9.97 TLR9 TLR8 TLR7 TLR4 TLR3
27 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.97 TLR9 TLR8 TLR7 TLR5 TLR4 TLR2
28 positive regulation of interleukin-6 production GO:0032755 9.97 TNF TLR9 TLR8 TLR7 TLR4 TLR3
29 positive regulation of interleukin-12 production GO:0032735 9.96 TLR9 TLR4 TLR3 TLR2
30 positive regulation of interleukin-10 production GO:0032733 9.96 TLR9 TLR4 TLR2 IL6
31 lipopolysaccharide-mediated signaling pathway GO:0031663 9.94 TNF TLR4 TLR2 MYD88
32 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.93 TNF TLR4 MYD88 IL6
33 cellular response to interferon-gamma GO:0071346 9.92 TLR4 TLR3 TLR2
34 toll-like receptor 9 signaling pathway GO:0034162 9.92 TLR9 TLR8 TLR7 MYD88
35 I-kappaB phosphorylation GO:0007252 9.92 TLR9 TLR7 TLR4 TLR3 TLR2
36 regulation of inflammatory response GO:0050727 9.91 TNF TLR4 MYD88
37 negative regulation of interleukin-6 production GO:0032715 9.91 TNF TLR9 TLR4
38 toll-like receptor signaling pathway GO:0002224 9.91 TLR9 TLR8 TLR7 TLR5 TLR4 TLR3
39 apoptotic signaling pathway GO:0097190 9.9 TNF TLR4 TLR3
40 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.9 TNF IL6 IL2
41 regulation of protein phosphorylation GO:0001932 9.89 TNF TLR8 TLR7
42 positive regulation of T cell proliferation GO:0042102 9.89 IL6 IL2 CD4
43 positive regulation of smooth muscle cell proliferation GO:0048661 9.89 TNF MYD88 IL6
44 humoral immune response GO:0006959 9.89 TNF IL6 IFNA1
45 regulation of cytokine secretion GO:0050707 9.89 TLR9 TLR8 TLR5 TLR2 TLR10
46 positive regulation of cytokine production GO:0001819 9.88 TNF TLR5 TLR3
47 positive regulation of nitric oxide biosynthetic process GO:0045429 9.88 TNF TLR5 TLR4
48 positive regulation of B cell proliferation GO:0030890 9.88 TLR9 TLR4 IL2
49 positive regulation of immunoglobulin production GO:0002639 9.86 TLR9 IL6 IL2
50 positive regulation of interleukin-17 production GO:0032740 9.85 MYD88 IL6 IL2

Molecular functions related to Superficial Basal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 10.01 TNF TLR8 TLR4 TLR3 TLR2 TLR10
2 cytokine activity GO:0005125 9.78 TNF IL6 IL2 IFNA1
3 double-stranded RNA binding GO:0003725 9.67 TLR8 TLR7 TLR3
4 NAD+ nucleotidase, cyclic ADP-ribose generating GO:0061809 9.54 TLR4 TLR2 TLR10
5 siRNA binding GO:0035197 9.51 TLR9 TLR7
6 NAD(P)+ nucleosidase activity GO:0050135 9.5 TLR4 TLR2 TLR10
7 signaling receptor activity GO:0038023 9.5 TLR8 TLR5 TLR4 TLR3 TLR2 TLR10
8 Toll-like receptor binding GO:0035325 9.46 TLR2 MYD88
9 pattern recognition receptor activity GO:0038187 9.46 TLR9 TLR8 TLR7 TLR2
10 lipopolysaccharide receptor activity GO:0001875 9.43 TLR4 TLR2
11 interleukin-1 receptor binding GO:0005149 9.43 TLR9 TLR5 MYD88
12 transmembrane signaling receptor activity GO:0004888 9.28 TLR9 TLR8 TLR7 TLR5 TLR4 TLR3
Sources

Sources for Superficial Basal Cell Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....